Qiagen to Acquire SABiosciences

Qiagen has signed an agreement to acquire SABiosciences Corporation, a privately-held developer and manufacturer of disease- and pathway-focused Polymerase Chain Reaction (PCR) assay panels. The transaction is valued at US$90 million in cash (subject to customary purchase price adjustments) and is expected to close in late December 2009.

Peer Schatz, CEO of Qiagen said, “These assay panels are designed for use with and leveraged by our sample and assay technologies and can be run on our instruments. The addition of SABiosciences will boost our biological content engine to yield diagnostic content for prevention, profiling, and, most significantly, personalized healthcare.”